Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:19 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo (PBO) Clear all
Completed Phase 3 Interventional Results available

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

NCT02544451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Nov 1, 2026, 9:19 PM EST
Recruiting Phase 2Phase 3 Interventional

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

NCT05855369
View directory record Official record
Conditions
Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions
Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO)
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

NCT05447286
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NYX-783, Placebo, Oxycodone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 58 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242446
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
54
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

NCT01096979
View directory record Official record
Conditions
Subcutaneous Abdominal Adiposity
Interventions
LIPO-102, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Anaheim, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 2 Interventional Results available

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
127
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 2 Interventional Results available

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

NCT00833040
View directory record Official record
Conditions
Cancer, Pain
Interventions
Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Montebello, California • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT04294667
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

NCT02633527
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 2Phase 3 Interventional Results available

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04857983
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 2 Interventional

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

NCT04880031
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
48
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
LY3202626, Placebo (Part A, B, C), Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02333071
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Bremelanotide, Placebo
Drug · Other
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Nov 1, 2026, 9:19 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

NCT02069366
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Nov 1, 2026, 9:19 PM EST
Terminated Phase 2 Interventional Results available

Neurosteroids in PTSD - Biomarkers to Therapeutics

NCT03491007
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
DHEA
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Nov 1, 2026, 9:19 PM EST
Terminated Phase 2 Interventional

Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

NCT00928317
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ART621, Placebo
Drug
Lead sponsor
Arana Therapeutics Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Tampa, Florida • Springfield, Illinois • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Nov 1, 2026, 9:19 PM EST
Completed Phase 3 Interventional Results available

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03410992
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 1, 2026, 9:19 PM EST